drugset
drugset / Trial / NCT07218341

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 ↗

Phase 4 Recruiting 150 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Timeline

Start
2026-03-09
Primary completion
2030-05
Completion
2032-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Idelalisib Small molecule — Oral
Subject Pirtobrutinib Other / unclassified — Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma